Tenderwize
Retour à la recherche

Open house drug discount agreements Ranibizumab injection solution vial

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Mar 05, 2027 · 188 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Ranibizumab in der Darreichungsform Injektionslösung in der Durchstechflasche, ATC S01LA04

60/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

60 / 100

Complexité

20 / 100

Facteurs de risque

No value or volume estimates available; may attract many participants, diluting potential benefit.

Open-house agreements automatically terminate if a standard competitive discount agreement for the same substance is si...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Supply of Ranibizumab (ATC S01LA04) in injection solution form in vial
  • Participation in a non-exclusive drug discount scheme with AOK Bayern
Afficher le résumé complet

This is an open-house model for non-exclusive drug discount agreements (Rabattverträge) for the active substance Ranibizumab (injection solution, vial, ATC S01LA04) with AOK Bayern. It is not a traditional procurement procedure; any eligible pharmaceutical company can join under identical, non-negotiable terms. The contract period is from 1 May 2025 to 30 April 2027, with possible early termination. No estimated value is published. Only one lot is identified.

Risques

No value or volume estimates available; may attract many participants, diluting potential benefit.

Open-house agreements automatically terminate if a standard competitive discount agreement for the same substance is si...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies are eligible to participate

Administrative

  • Must submit a signed self-declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
  • Contract, annex specifying covered medicines, and self-declaration must be submitted in paper (2 copies) or electronically with qualified electronic signature

Les exigences peuvent être incomplètes.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house drug discount agreements Ranibizumab injection solution vial

Non-exclusive discount agreements for Ranibizumab injection solution in vial form. All interested pharmaceutical companies meeting eligibility can sign identical contracts.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Apr 2025 - Apr 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Mar 05, 2027

Détails de la procédure

Date de publication
18 Mar 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
176237-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30